Zacks Research Has Negative Outlook of CPRX FY2025 Earnings

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Investment analysts at Zacks Research lowered their FY2025 EPS estimates for shares of Catalyst Pharmaceuticals in a research note issued on Wednesday, March 19th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn $2.02 per share for the year, down from their previous forecast of $2.07. The consensus estimate for Catalyst Pharmaceuticals' current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals' FY2026 earnings at $2.25 EPS and FY2027 earnings at $2.37 EPS.

CPRX has been the subject of several other research reports. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Robert W. Baird raised their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. Bank of America reaffirmed a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Finally, Stephens reiterated an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Catalyst Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $32.29.

Remove Ads

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX traded down $0.08 during mid-day trading on Monday, reaching $25.66. 906,791 shares of the company's stock were exchanged, compared to its average volume of 1,347,831. The company's 50-day moving average is $22.46 and its 200-day moving average is $21.67. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of 21.75, a PEG ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals has a 52-week low of $14.47 and a 52-week high of $26.16.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 7.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 21,419 shares of the biopharmaceutical company's stock valued at $447,000 after acquiring an additional 1,402 shares in the last quarter. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals during the fourth quarter worth $29,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Catalyst Pharmaceuticals in the fourth quarter worth $3,733,000. Armis Advisers LLC acquired a new position in Catalyst Pharmaceuticals during the fourth quarter worth about $306,000. Finally, Mackenzie Financial Corp grew its holdings in shares of Catalyst Pharmaceuticals by 132.9% in the 4th quarter. Mackenzie Financial Corp now owns 34,531 shares of the biopharmaceutical company's stock worth $721,000 after acquiring an additional 19,705 shares during the period. Hedge funds and other institutional investors own 79.22% of the company's stock.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.00% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.